Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 9 Sept 2015 |
| U.S. FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma | 4 Sept 2015 |
| Major Shareholder Announcement | 2 Sept 2015 |
| Genmab’s Total Number of Voting Rights and Total Share Capital | 31 Aug 2015 |
| Data Published in The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses in Heavily Pre-treated Relapsed or Refractory Multiple Myeloma Patients | 27 Aug 2015 |